MIF and D-DT are potential disease severity modifiers in male MS subjects.

导出 OA

翻译打印收藏纠错

作者： Gil,Benedek ^[1] ; Roberto,Meza-Romero ^[2] ; Kelley,Jordan ^[1] ; Ying,Zhang ^[2] ; Ha,Nguyen ^[1] ; Gail,Kent ^[2] ; Jia,Li ^[1] ; Edwin,Siu ^[2] ; Jenny,Frazer ^[1] ; Marta,Piecychna ^[2] ; Xin,Du ^[1] ; Antoine,Sreih ^[2] ; Lin,Leng ^[3] ; Jack,Wiedrick ^[3] ; Stacy J,Caillier ^[3] ; Halina,Offner ^[3] ; Jorge R,Oksenberg ^[3] ; Vijayshree,Yadav ^[3] ; Dennis,Bourdette ^[3] ; Richard,Bucala ^[4] ; Arthur A,Vandenbark ^[5]

作者单位： Neuroimmunology Research, VA Portland Health Care System, Portland, OR 97239. ^[1] Tykeson MS Research Laboratory, Department of Neurology UHS-46, Oregon Health & Science University, Portland, OR 97239. ^[2] Department of Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, CT 06520. ^[3] Biostatistics & Design Program, School of Public Health, Oregon Health & Science University, Portland, OR 97239. ^[4] Department of Neurology, University of California, San Francisco, CA 94143. ^[5] Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR 97239. ^[6] Department of Neurology, Oregon Health & Science University, Portland, OR 97239. ^[7] Neuroimmunology Research, VA Portland Health Care System, Portland, OR 97239; vandenba@ohsu.edu. ^[8] Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239. ^[9]

关键词 disease modifier multiple sclerosis sex differences